sub:assertion {
  <http://purl.obolibrary.org/obo/MONDO_0005090> a bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/MONDO_0005090> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/DRUGBANK:DB01267> ;
    a rdf:Statement ;
    rdfs:label "Paliperidone is FDA-approved for schizophrenia aged 12-17. However, the pharmacologic portfolio, extrapolation from adult studies, and the long track record of the parent drug, risperidone in child/adolescent psychiatric (CAP) population might expand its therapeutic potential. An 8-week open-label study [9] examined paliperidone monotherapy for acute mania, mixed, or hypomanic episode in pediatric patients (n = 15, 6–17 years of age) with bipolar spectrum disorders. At the end of follow-up period, 11 subjects (73%) completed the study; treatment with paliperidone was associated with a 60% response rate (50% decrease in the Young Mania Rating Scale) and 40% remission (YMRS <12)" ;
    bl:has_population_context sub:context ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:publications <https://pubmed.ncbi.nlm.nih.gov/31096228> ;
    bl:relation nkg:OffLabelIndication .
  sub:context a bl:Cohort ;
    rdfs:label "Children and adolescents (6-17 years)" .
  <https://identifiers.org/DRUGBANK:DB01267> a bl:Drug .
}